Health and Science
CDC says massive cyclospora outbreak is now in nine states
The four newly linked states — Illinois, Kansas, Oklahoma and Pennsylvania — join Indiana, Kentucky, Ohio, West Virginia and hard-hit Michigan.
Novo Nordisk sues Eli Lilly, alleging misleading GLP-1 advertising
Novo asked the court to permanently stop Lilly from running the “deceptive” ads and require the drugmaker to issue corrective advertising.
The FDA made a big reversal in its cyclosporiasis probe, but it still thinks iceberg lettuce is to blame
The FDA’s investigation into the source of the cyclosporiasis outbreak is causing confusion as companies and consumers alike navigate new updates.
What to know about testosterone replacement therapy as the U.S. military plans to test troops
While some research has shown benefits for patients who qualify, questions remain about the therapy’s long-term risks and use among men without a medical need.
UnitedHealth blows past estimates, hikes earnings outlook as it reins in costs
The healthcare giant is working to stabilize margins by shrinking membership, exiting unprofitable contracts and pouring $1.5 billion into AI.
A tiny GLP-1 implant is the latest bet to help patients maintain their weight loss
Vivani Medical is developing an implant of semaglutide, the active ingredient in Novo Nordisk’s obesity injection Wegovy and diabetes counterpart Ozempic.
Medicare will start covering obesity drugs for the first time. Here’s what patients should know
The move could unlock millions of new patients for Novo Nordisk and Eli Lilly and expand access to medications that were previously out of reach for seniors.
Eli Lilly, Regeneron among first companies selected for FDA initiative to speed review of new manufacturing facilities
Eli Lilly and Regeneron are among the first seven companies the FDA has selected for its PreCheck Pilot Program, CNBC has learned.
Seniors in Medicare are about to get landmark obesity drug coverage — but many may not know it yet
Many seniors may be unaware of the landmark coverage shift starting on July 1, with limited advertising seen from the government or Eli Lilly and Novo.
Estrogen patches are hard to find, and it may not be resolved any time soon
Estrogen patches are in short supply as demand for menopause treatments skyrockets, and it could take at least a year for manufacturers to catch up.